Use
Azapropazone, which has anti-inflammatory, analgesic and
antipyretic activity, was introduced in 1970 for the treatment of rheumatic
disorders. Although sometimes classified as a pyrazolone derivative, the
relationship with this group of compounds has been disputed and classification as
a benzotriazine derivative might be preferable. Although, to date, it has not been
associated with blood dyscrasias, some regulatory authorities have applied the
same rigorous restrictions to its indications as they have applied to pyrazolone
derivatives. The World Health Organization was informed that as of December 1987
azapropazone was available in some 27 countries.